227 352

Cited 0 times in

Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy.

Authors
 Yongjung Park  ;  Jun Yong Park  ;  Kwang-Hyub Han  ;  Hyon-Suk Kim 
Citation
 HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, Vol.11(5) : 499-506, 2012 
Journal Title
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
ISSN
 1499-3872 
Issue Date
2012
MeSH
Adult ; Antiviral Agents/therapeutic use* ; Cytokines/blood* ; DNA, Viral/blood ; Female ; Hepatitis B, Chronic/drug therapy* ; Hepatitis B, Chronic/immunology ; Hepatitis B, Chronic/virology ; Humans ; Interferon-alpha/therapeutic use* ; Male ; Polyethylene Glycols/therapeutic use* ; Predictive Value of Tests ; Recombinant Proteins/therapeutic use
Keywords
chronic hepatitis B ; cytokine ; hepatitis B virus ; peginterferon ; protein chip array
Abstract
The relationship between cytokines and responses to peginterferon alpha-2a treatment in chronic hepatitis B patients has not yet been fully elucidated. We analyzed the serum levels of interleukin (IL)-1alpha, IL-1beta, IL-2, IL-4, IL-6, IL-8, IL-10, vascular endothelial growth factor, interferon-gamma, tumor necrosis factor-alpha, monocyte chemotactic protein-1 (MCP1) and epidermal growth factor during the treatment with peginterferon alpha-2a.

METHODS: Ninety-three serum samples from 20 chronic hepatitis B patients were collected before, during and after 48 weeks of peginterferon therapy and were assayed for 12 cytokines. The patients were categorized as either virologic responders (VRs) or non-responders (NRs) according to their HBV DNA levels taken at 6th month during treatment. The Evidence Investigator (Randox, Antrim, UK), a protein chip analyzer, was used to quantify cytokines.

RESULTS: Among the 12 cytokines, the levels of MCP1 were increased and the levels of IL-4 were decreased during the treatment in VRs. However these cytokines were not significantly changed in NRs in the treatment phases. Area under the receiver operating characteristic curve (AUROC) value of HBV DNA measured before the treatment was 0.81 in predicting VRs, and that of the baseline MCP1 was 0.76. IL-6 levels at 3rd and 6th months during the treatment also showed AUROC values 0.85 and 0.78 respectively in predicting sustained VRs.

CONCLUSION: Serum cytokine levels reflect the pathological differences of individual treatment phases and could also be useful in monitoring responses to peginterferon treatment in chronic hepatitis B patients.
Files in This Item:
T201203472.pdf Download
DOI
23060395
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyon Suk(김현숙) ORCID logo https://orcid.org/0000-0001-5662-7740
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/90348
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links